609O Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)
Ben Tran, Lisa G. Horvath, Tanya B. Dorff, M. Rettig, Martijn P. Lolkema, J-P. Machiels, Sylvie Rottey, Karen A. Autio, Richard Greil, Nabil Adra, Charlotte Lemech, Mukul Minocha, F-C. Cheng, Hosein Kouros‐Mehr, Karim Fizazi
Topics & Concepts
MedicineProstate cancerInternal medicineTolerabilityRashAdverse effectPembrolizumabOncologyTumor lysis syndromeTaxaneProgressive diseaseCytokine release syndromeGastroenterologyCancerImmunotherapyChemotherapyBreast cancerChimeric antigen receptorCAR-T cell therapy researchCancer Immunotherapy and BiomarkersProstate Cancer Treatment and Research